COLOSSAL BIOSCIENCES TARGETS $20B–$30B VALUATION
■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE
De-extinction startup Colossal Biosciences is in talks to raise new capital at a valuation between $20 billion and $30 billion, potentially doubling or tripling its previous valuation.
■ MORE FROM THE STARTUPS DESK
AI CRM startup Lightfield, formerly known as Tome, secured $47M in Series A funding led by Andreessen Horowitz. The company has now raised $127M total across funding rounds.
Euno, an enterprise AI context platform, secured $23 million in Series A funding led by N47. The platform reconstructs data flow and meaning across environments to provide AI agents with contextual information.
Sequoia Capital co-led a $25 million Series A funding round for Cymphony, valuing the enterprise security startup at over $100 million. The investment reflects growing investor focus on AI agent security risks in enterprise environments.
Savvy Wealth, which provides software and back-office infrastructure for independent financial advisors, secured $100 million in Series C funding led by Halo Fund. The round brings the fintech company's total funding to over $200 million.